Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail as well as corporate materials mailed to you.

Recent News:

 

1/26/2012 Hemispherx Biopharma Gains Regulatory Approval in Latin America
…Alferon® under the brand name “Naturaferon” approved in Argentina


1/17/2012 Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon® LDO
…New Patents Establish Unique Mechanism of Broad-Spectrum Protection


1/11/2012 FDA Grants Hemispherx Biopharma Extension in its Pending New Drug Application (NDA) for the Treatment of Chronic Fatigue Syndrome (CFS)
…New Governmental Research Expands Medical and Economic Impact of Untreated CFS


12/8/2011 Hemispherx Biopharma’s 2011 Stockholder Annual Meeting Final Results
Proposal To Amend Certificate of Incorporation Receives Stockholder Approval


11/9/2011 Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 from the 2011 Annual Meeting of Stockholders
…Stockholder Action Requested – Please Vote


More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Dianne Will
Phone:  518-398-6222
Fax:  518-398-6369
or send an e-mail to:
ir@hemispherx.net